OpenLB
Open Library of Bioscience
Advanced Search
Hepatology research : the official journal of the Japan Society of Hepatology
Jan, 2022;52 (1): 5-66.

Report of the 22nd nationwide follow-up Survey of Primary Liver Cancer in Japan (2012-2013).

Masatoshi Kudo, Namiki Izumi, Norihiro Kokudo, Michiie Sakamoto, Shuichiro Shiina, Tadatoshi Takayama, Ryosuke Tateishi, Osamu Nakashima, Takamichi Murakami, Yutaka Matsuyama, Arata Takahashi, Hiroaki Miyata, Shoji Kubo
Author Information
  1. Masatoshi Kudo: Liver Cancer Study Group of Japan, Follow-up Survey Committee, Japan.
  2. Namiki Izumi: Liver Cancer Study Group of Japan, Follow-up Survey Committee, Japan.
  3. Norihiro Kokudo: Liver Cancer Study Group of Japan, Follow-up Survey Committee, Japan.
  4. Michiie Sakamoto: Liver Cancer Study Group of Japan, Follow-up Survey Committee, Japan.
  5. Shuichiro Shiina: Liver Cancer Study Group of Japan, Follow-up Survey Committee, Japan.
  6. Tadatoshi Takayama: Liver Cancer Study Group of Japan, Follow-up Survey Committee, Japan.
  7. Ryosuke Tateishi: Liver Cancer Study Group of Japan, Follow-up Survey Committee, Japan.
  8. Osamu Nakashima: Liver Cancer Study Group of Japan, Follow-up Survey Committee, Japan.
  9. Takamichi Murakami: Liver Cancer Study Group of Japan, Follow-up Survey Committee, Japan.
  10. Yutaka Matsuyama: Liver Cancer Study Group of Japan, Follow-up Survey Committee, Japan.
  11. Arata Takahashi: Liver Cancer Study Group of Japan, Follow-up Survey Committee, Japan.
  12. Hiroaki Miyata: Liver Cancer Study Group of Japan, Follow-up Survey Committee, Japan.
  13. Shoji Kubo: Liver Cancer Study Group of Japan, Follow-up Survey Committee, Japan.
PMID: 34050584 DOI: 10.1111/hepr.13675

Abstract

In the 22nd Nationwide Follow-up Survey of primary liver cancer in Japan, data from 21 155 newly registered patients and 43 041 previously registered follow-up patients were compiled from 538 institutions over a 2-year period from January 1, 2012 to December 31, 2013. Basic statistics compiled for patients newly registered in the 22nd survey were cause of death, past medical history, clinical diagnosis, imaging diagnosis, treatment-related factors, pathologic diagnosis, recurrence status and autopsy findings. Compared with the previous 21st survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, had more female patients, more patients with non-B non-C HCC, smaller tumor diameter and was more frequently treated with hepatectomy. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma (combined HCC and intrahepatic cholangiocarcinoma) by treatment type and background characteristics for patients newly registered between 2002 and 2013 whose final outcome was survival or death. Median overall survival and cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter or Child-Pugh grade) and by treatment type (hepatectomy, radiofrequency ablation therapy, transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy and systemic therapy). The same values were also calculated according to registration date by dividing patients newly registered between 1978 and 2013 into five time period groups. The data obtained from this nationwide follow-up survey are expected to contribute to advancing clinical research and treatment of primary liver cancer worldwide.

Keywords

combined hepatocellular cholangiocarcinoma cumulative survival rate hepatocellular carcinoma intrahepatic cholangiocarcinoma liver cancer study group of Japan nationwide follow-up survey nationwide survey

References

  1. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. 1st ed. Tokyo: Kanehara & Co., Ltd.; 1983. (in Japanese).
  2. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. 2nd ed. Tokyo: Kanehara & Co., Ltd.; 1987. (in Japanese).
  3. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. 3rd ed. Tokyo: Kanehara & Co., Ltd.; 1992. (in Japanese).
  4. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. 4th ed. Tokyo: Kanehara & Co., Ltd.; 2000. (in Japanese).
  5. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. 5th ed. Tokyo: Kanehara & Co., Ltd.; 2008. (in Japanese).
  6. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. 5th revised ed. Tokyo: Kanehara & Co., Ltd.; 2009. (in Japanese).
  7. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. 6th ed. Tokyo: Kanehara & Co., Ltd.; 2015. (in Japanese).
  8. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. 6th revised ed. Tokyo: Kanehara & Co., Ltd.; 2019. (in Japanese).
  9. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. Tokyo: Kanehara & Co., Ltd.; 1997.
  10. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. 2nd English edition. Tokyo: Kanehara & Co., Ltd.; 2003.
  11. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. 3rd English edition. Tokyo: Kanehara & Co.,Ltd.; 2010.
  12. Murakami F, Okamura J, Oshiro T, Ota M, Kubota S, Hama M, et al. Surgical treatment of liver disease. Shinryo. 1970;23:265-77.
  13. Ishikawa K, Kosaka K. Outcomes of surgical treatment of primary liver cancer. Kanzo. 1973;14:409-10.
  14. Ishikawa K. Survey and follow-up study of primary liver cancer in Japan: report 3. Kanzo. 1976;17:460-5. (in Japanese).
  15. Ishikawa K. Survey and follow-up study of primary liver cancer in Japan: report 4. Kanzo. 1979;20:433-41. (in Japanese).
  16. Okuda K. Liver cancer study group of Japan. Primary liver cancers in Japan. Cancer. 1980;45:2663-9.
  17. Liver Cancer Study Group of Japan. Report of the 5th Nationwide Follow-up Survey of Primary Liver Cancer (1978-1979). Kyoto: Liver Cancer Study Group of Japan; 1982. (in Japanese).
  18. Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan: report 5. Kanzo. 1982;23:675-81. (in Japanese).
  19. Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Cancer. 1984;54:1747-55.
  20. Liver Cancer Study Group of Japan. Report of the 6th Nationwide Follow-up Survey of Primary Liver Cancer (1980-1981). Kyoto: Liver Cancer Study Group of Japan; 1984. (in Japanese).
  21. Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan: report 6. Kanzo. 1985;26:254-62. (in Japanese).
  22. Tsukuma H, Fujimoto I, Oshima A, Liver Cancer Study Group of Japan. Estimation of risk for hepatocellular carcinoma among HBsAg carriers and heavy drinkers in Japan. Kanzo. 1986;27:1281-9. (in Japanese).
  23. Liver Cancer Study Group of Japan. Report of the 7th nationwide follow-up survey of primary liver cancer (1982-1983). Kyoto: Liver Cancer Study Group of Japan; 1986. (in Japanese).
  24. Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan: report 7. Kanzo. 1986;27:1161-9. (in Japanese).
  25. Liver Cancer Study Group of Japan. Primary liver cancer in Japan Sixth report. Cancer. 1987;60:1400-11.
  26. Liver Cancer Study Group of Japan. Report of the 8th nationwide follow-up survey of primary liver cancer (1984-1985). Kyoto: Liver Cancer Study Group of Japan; 1988. (in Japanese).
  27. Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan: report 8. Kanzo. 1988;29:1619-26. (in Japanese).
  28. The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg. 1989;19:98-129.
  29. Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Ann Surg. 1990;211:277-87.
  30. Liver Cancer Study Group of Japan. Report of the 9th nationwide follow-up survey of primary liver cancer (1986-1987). Kyoto: Liver Cancer Study Group of Japan; 1990. (in Japanese).
  31. Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan: report 9. Kanzo. 1991;32:1138-47. (in Japanese).
  32. Tobe T, Kameda H, Okudaira M, Ohto M, Endo Y, Mito M, et al. editors. Primary liver cancer in Japan. Tokyo: Springer-Verlag; 1992.
  33. Liver Cancer Study Group of Japan. Report of the 10th nationwide follow-up survey of primary liver cancer (1988-1989). Kyoto: Liver Cancer Study Group of Japan; 1992. (in Japanese).
  34. Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan: report 10. Kanzo. 1993;34:805-13. (in Japanese).
  35. Liver Cancer Study Group of Japan. Predictive factors for Long Term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer. 1994;74:2772-880.
  36. Liver Cancer Study Group of Japan. Report of the 11th nationwide follow-up survey of primary liver cancer (1990-1991). Kyoto: Liver Cancer Study Group of Japan; 1994. (in Japanese).
  37. Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan: report 11. Kanzo. 1995;36:208-18. (in Japanese).
  38. Liver Cancer Study Group of Japan. Report of the 12th nationwide follow-up survey of primary liver cancer (1992-1993). Kyoto: Liver Cancer Study Group of Japan; 1997. (in Japanese).
  39. Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan: report 12. Kanzo. 1997;38:317-30. (in Japanese).
  40. Liver Cancer Study Group of Japan. Report of the 13th nationwide follow-up survey of primary liver cancer (1994-1995). Kyoto: Liver Cancer Study Group of Japan; 1998. (in Japanese).
  41. Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan: report 13. Kanzo. 1999;40:288-300. (in Japanese).
  42. Liver Cancer Study Group of Japan. Report of the 14th nationwide follow-up survey of primary liver cancer (1996-1997). Kyoto: Liver Cancer Study Group of Japan; 2000. (in Japanese).
  43. Liver Cancer Study Group of Japan. Report of the 14th nationwide follow-up survey of primary liver cancer (1996-1997). Kanzo. 2000;41:799-811. (in Japanese).
  44. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi M, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000;32:1224-9.
  45. Liver Cancer Study Group of Japan. Report of the 15th nationwide follow-up survey of primary liver cancer (1998-1999). Kyoto: Liver Cancer Study Group of Japan; 2002. (in Japanese).
  46. Liver Cancer Study Group of Japan. Report of the 15th nationwide follow-up survey of primary liver cancer (1998-1999). Kanzo. 2003;44:157-75. (in Japanese).
  47. Ikai I, Itai Y, Okita K, Omata M, Kojiro M, Kobayashi K, et al. Report of the 15th follow-up survey of primary liver cancer. Hepatol Res. 2004;28:21-9.
  48. Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, et al. Re-evaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer. 2004;101:796-802.
  49. Liver Cancer Study Group of Japan. Report of the 16th nationwide follow-up survey of primary liver cancer (2000-2001). Kyoto: Liver Cancer Study Group of Japan; 2004. (in Japanese).
  50. Liver Cancer Study Group of Japan. Report of the 16th nationwide follow-up survey of primary liver cancer (2000-2001). Kanzo. 2004;46:234-54. (in Japanese).
  51. Liver Cancer Study Group of Japan. Report of the 17th nationwide follow-up survey of primary liver cancer (2002-2003). Kyoto: Liver Cancer Study Group of Japan; 2007. (in Japanese).
  52. Liver Cancer Study Group of Japan. Report of the 17th nationwide follow-up survey of primary liver cancer (2002-2003). Kanzo. 2007;48:117-40. (in Japanese).
  53. Ikai I, Arii S, Ichida T, Okita K, Omata M, Kojiro M, et al. Ichida Report of the 16th follow-up survey of primary liver cancer. Hepatol Res. 2005;32:163-72.
  54. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37:676-91.
  55. Takayasu K, Arii S, Ikai I, Omata K, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461-9.
  56. Ikai I, Takayasu K, Omata M, Okita K, Nakamura Y, Matsuyama Y, et al. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterology. 2006;41:884-92.
  57. Minagawa M, Ikai I, Matsuyama Y, Yamao Y, Makuuchi M. Staging of Hepatocellular Carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:909-22.
  58. Eguchi S, Kanematsu T, Arii S, Okazaki M, Okita K, Omata M, et al. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery. 2008;143:469-75.
  59. Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, et al. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol. 2008;49:589-94.
  60. Liver Cancer Study Group of Japan. Report of the 18th Nationwide Follow-up Survey of Primary Liver Cancer (2004-2005). Kyoto: Liver Cancer Study Group of Japan; 2009. (in Japanese).
  61. Hasegawa K, Makuuchi M, Kudo M, Okazaki M. Liver Cancer Study Group of Japan, et al. Hepatectomy versus radiofrequency ablation for early hepatocellular carcinoma: reply. J Hepatol. 2009;50:1052-3.
  62. Liver Cancer Study Group of Japan. Report of the 18th nationwide follow-up survey of primary liver cancer (2004-2005). Kanzo. 2009;50:1051-6. (in Japanese).
  63. Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR. 2010;194:830-7.
  64. Ikai I, Kudo M, Arii S, Omata K, Kojiro M, Sakamoto M, et al. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2010;40:1043-59.
  65. Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, Sakamoto M, et al. Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg. 2011;98:552-7.
  66. Higashi T, Hasegawa K, Kokudo K, Makuuchi M, Izumi M, Ichida T, et al. Demonstration of quality of care measurement using the Japanese liver cancer registry. Hepatol Res. 2011;41:1208-15.
  67. Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol. 2012;56:886-92.
  68. Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Ichida T, et al. Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm. Liver Int. 2013;33:762-70.
  69. Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol. 2013;58:724-9.
  70. Nouso K, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan. Br J Cancer. 2013;109:1904-7.
  71. Aoki T, Kokudo N, Matsuyama Y, Izumi N, Ichida T, Kudo M, et al. Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1,160 cases from a nationwide survey. Ann Surg. 2014;259:532-42.
  72. Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, et al. Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to therapeutic impact. Ann Surg. 2014;259:336-45.
  73. Hasegawa K, Makuuchi M, Kokudo N, Izumi N, Ichida T, Kudo M, et al. Impact of histologically confirmed lymph node metastases on the patient survival after surgical resection for hepatocellular carcinoma: report of a Japanese nationwide survey. Ann Surg. 2014;259:166-70.
  74. Liver Cancer Study Group of Japan. Report of the 19th nationwide follow-up survey of primary liver cancer (2006-2007). Osaka: Liver Cancer Study Group of Japan; 2014. (in Japanese).
  75. Kitai S, Kudo M, Izumi N, Kaneko S, Ku Y, Kokudo N, et al. Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score, and BCLC system) in 4,649 cases from a Japanese nationwide survey. Digest Dis. 2014;32:717-24.
  76. Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, et al. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11, 950 patients. Ann Surg. 2015;261:513-20.
  77. Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Izumi M, Kadoya M, et al. Proposal of a new staging system for intrahepatic cholangiocarcinoma: analysis of surgical patients from a nationwide survey of the liver cancer study group of Japan. Cancer. 2016;122:61-70.
  78. Liver Cancer Study Group of Japan. Report of the 19th nationwide follow-up survey of primary liver cancer (2006-2007). Kanzo. 2016;57:45-73. (in Japanese).
  79. Kitai S, Kudo M, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, et al. Survival benefit of locoregional treatment for hepatocellular carcinoma with advanced liver cirrhosis. Liver Cancer. 2016;5:175-89.
  80. Kudo M, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, et al. Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver Cancer. 2016; 5:190-7.
  81. Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, et al. Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2016;46:372-90.
  82. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kaneoko S, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65:938-43.
  83. Toyoda H, Tada T, Johnson PJ, Izumi N, Kadoya M, Kaneko S, et al. Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. J Gastroenterol. 2017;52:1112-21.
  84. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, et al. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. Hepatology. 2017;66:510-7.
  85. Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer. 2017;6:325-36.
  86. Takayasu K, Arii S, Sakamoto M, Matasuyama Y, Kudo M, Kaneko S, et al. Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting. Liver Int. 2018;38:484-93.
  87. Kaibori M, Yoshii K, Hasegawa K, Ogawa A, Kubo S, Tateishi R, et al. Treatment optimization for hepatocellular carcinoma in elderly patients in a Japanese nationwide cohort. Ann Surg. 2019;270:121-30.
  88. Kaibori M, Yoshii K, Yokota I, Hasegawa K, Nagashima F, Kubo S, et al. Impact of advanced age on survival in patients undergoing resection of hepatocellular carcinoma: report of a Japanese nationwide survey. Ann Surg. 2019;269:692-9.
  89. Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, et al. Prediction of prognosis of intermediate stage HCC patients-validation of tumor marker score in nationwide database in Japan. Liver Cancer. 2019;8:403-11.
  90. Liver Cancer Study Group of Japan. Report of the 20th nationwide follow-up survey of primary liver cancer (2008-2009). Osaka: Liver Cancer Study Group of Japan; 2019. (in Japanese).
  91. Aoki T, Kubota K, Hasegawa K, Kubo S, Izumi N, Kokudo N, et al. Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma. Br J Surg. 2020;107:113-20.
  92. Watanabe Y, Matsuyama Y, Izumi N, Kubo S, Kokudo N, Sakamoto M, et al. Effect of surgical margin width after R0 resection for intrahepatic cholangiocarcinoma: a nationwide survey of the Liver Cancer Study Group of Japan. Surgery. 2020;167:793-802.
  93. Liver Cancer Study Group of Japan. Report of the 20th nationwide follow-up survey of primary liver cancer (2008-2009). Kanzo. 2019;60:258-93. (in Japanese).
  94. Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, et al. Report of the 20th nationwide follow-up Survey of primary liver cancer in Japan. Hepatol Res. 2020;50:15-46.
  95. Fukami Y, Kaneoka Y, Maeda A, Kumada T, Tanaka J, Akita T, et al. Liver resection for multiple hepatocellular carcinomas: a Japanese nationwide survey. Ann Surg. 2020;272:145-54.
  96. Liver Cancer Study Group of Japan. Report of the 21st nationwide follow-up survey of primary liver cancer (2010-2011). Osaka: Liver Cancer Study Group of Japan; 2020. (in Japanese).
  97. Liver Cancer Study Group of Japan. Report of the 21st nationwide follow-up survey of primary liver cancer (2010-2011). Kanzo. 2020;61:645-91. (in Japanese).
  98. Kudo M, Izumi N, Kokudo N, et al. Report of the 21st follow-up survey of primary liver cancer in Japan (2010-2011). Hepatol Res. 2020. (Epub ahead of print).
  99. Liver Cancer Study Group of Japan. Report of the 22nd nationwide follow-up survey of primary liver cancer (2012-2013). Osaka: Liver Cancer Study Group of Japan; 2021. (in Japanese).
  100. Liver Cancer Study Group of Japan. Report of the 22nd nationwide follow-up survey of primary liver cancer (2012-2013). Kanzo. 2021. in press (in Japanese).
  101. Aoki T, Kubota K, Kubo S, Eguchi S, Izumi N, Kokudo N, et al. Analysis of patient outcome after non-curative resection for hepatocellular carcinoma using nationwide survey data in Japan. World J Surg. 2021;45:607-14.
  102. Liver Cancer Study Group of Japan. Response evaluation criteria in cancer of the liver. Kanzo. 1994;35:193-205. (in Japanese).
  103. Liver Cancer Study Group of Japan. Response evaluation criteria in cancer of the liver (2004 Revised Version). Kanzo. 2004;45:380-5. (in Japanese).
  104. Liver Cancer Study Group of Japan. Response evaluation criteria in cancer of the liver (2009 Revised Version). Kanzo. 2010;51:261-6. (in Japanese).
  105. Kudo M, Kubo S, Takayasu K, Sakamoto M, Tanaka M, Ikai I, et al. Response evaluation criteria in cancer of the liver (RECICL) proposed by the liver cancer study group of Japan (2009 revised version). Hepatol Res. 2010;40:686-92.
  106. Kudo M, Ueshima K, Kubo S, Sakamoto M, Tanaka M, Ikai I, et al. Response evaluation criteria in cancer of the liver (2015 Revised Version). Kanzo. 2015;56:116-21. (in Japanese).
  107. Kudo M, Ueshima K, Kubo S, Sakamoto M, Tanaka M, Ikai I, et al. Response evaluation criteria in cancer of the liver (RECICL) (2015 revised version). Hepatol Res. 2016;46:3-9.
  108. Kudo M, Ikeda M, Ueshima K, Sakamoto M, Shiina S, Tateishi R, et al. Tateishi R, et al, Response evaluation criteria in cancer of the liver (RECICL Version 5) (2019 Revised Version). Kanzo. 2019;60:55-62. (in Japanese).
  109. Kudo M, Ikeda M, Ueshima K, Sakamoto M, Shiina S, Tateishi R, et al. Response evaluation criteria in cancer of the liver version 5 (RECICL 2019 revised version). Hepatol Res. 2019;49:981-9.
  110. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan integrated staging score (JIS score). J Gastroenterol. 2003;38:207-15.
  111. Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40:1396-405.
Journal Article
Article has an altmetric score of 13

Word Cloud

Created with Highcharts 10.0.0patientsregisteredsurveyHCCsurvivalcholangiocarcinomanewlyfollow-updiagnosishepatocellularnationwide22ndJapan2013clinicalcalculatedintrahepaticcombinedtreatmentSurveyPrimaryLiverCancerdatacompiledperioddeathfactorscarcinomatimetumordiameterhepatectomyratestypebackgroundcumulativedividingtherapyarteriallivercancerNationwideFollow-up21 15543 041previously538institutions2-yearJanuary12012December31Basicstatisticscausepastmedicalhistoryimagingtreatment-relatedpathologicrecurrencestatusautopsyfindingsComparedprevious21stpopulationolderfemalenon-Bnon-CsmallerfrequentlytreatedCumulativecharacteristics2002whosefinaloutcomeMedianoverallcombinationsnumbertumorsChild-Pughgraderadiofrequencyablationtranscatheterchemoembolizationhepaticinfusionchemotherapysystemicvaluesalsoaccordingregistrationdate1978fivegroupsobtainedexpectedcontributeadvancingresearchprimaryworldwideReport2012-2013ratestudygroup

Similar Articles

Cited By